Key Points
- Thermo Fisher EVP Michael Shafer sold 25,500 shares at an average price of $600, worth $15.3 million, reducing his stake by 54.85%. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Thermo Fisher reported stronger-than-expected quarterly results, with EPS of $6.03 and revenue of $11.99 billion, up 10.5% year over year. The company reaffirmed fiscal 2026 EPS guidance of $24.93–$25.33.
- Analysts maintain a generally positive outlook, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $619.41; shares recently traded near $596.65.
Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) EVP Michael Shafer sold 25,500 shares of the firm's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Thermo Fisher Scientific Stock Performance
Shares of TMO stock opened at $596.65 on Friday. The stock has a market cap of $220.61 billion, a PE ratio of 32.10, a price-to-earnings-growth ratio of 2.45 and a beta of 0.85. The stock has a 50-day moving average of $527.07 and a 200-day moving average of $509.02. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $643.99.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. During the same quarter in the previous year, the company earned $4.28 earnings per share. The business's revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.
Thermo Fisher Scientific Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is currently 10.11%.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of TMO. Vanguard Group Inc. lifted its stake in Thermo Fisher Scientific by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company's stock valued at $19,778,774,000 after acquiring an additional 288,296 shares in the last quarter. J. Stern & Co. LLP raised its holdings in shares of Thermo Fisher Scientific by 58,006.4% in the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock valued at $18,258,082,000 after purchasing an additional 31,455,105 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Thermo Fisher Scientific in the second quarter worth $15,501,867,000. State Street Corp boosted its holdings in Thermo Fisher Scientific by 1.4% during the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company's stock worth $9,633,991,000 after purchasing an additional 229,630 shares during the last quarter. Finally, Capital World Investors grew its position in Thermo Fisher Scientific by 7.0% in the fourth quarter. Capital World Investors now owns 11,003,814 shares of the medical research company's stock valued at $6,376,229,000 after purchasing an additional 718,669 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
TMO has been the subject of a number of research analyst reports. Weiss Ratings raised Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, July 14th. Morgan Stanley raised their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Royal Bank Of Canada boosted their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a research report on Friday, July 24th. Piper Sandler raised their target price on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a "neutral" rating in a report on Monday, July 27th. Finally, Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a "market perform" rating and a $520.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $619.41.
Read Our Latest Stock Report on TMO
Thermo Fisher Scientific Company Profile
(
Get Free Report)
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
